Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Positive results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST were reported in 2025. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2.
Ja – Cogent Biosciences hat aktuell 15 offene Stellen auf JobsRadar, verteilt auf 18 Abteilungen und 3 Standorte. 4 davon wurden in den letzten 30 Tagen ausgeschrieben. Davon machen 15 Angaben zum Gehalt – im Median $200,000 pro Jahr, die meisten Angebote liegen zwischen $170,000 und $218,750. 3 kamen in den letzten 24 Stunden dazu; zuletzt aktualisiert am 16. September 2026 um 19:08 UTC.